Vol 1, No 3 (2010)
Review paper
Published online: 2010-07-27

open access

Page views 784
Article views/downloads 2289
Get Citation

Connect on Social Media

Connect on Social Media

Compliance during therapy of patients with chronic myeloid leukemia

Witold Prejzner
Hematologia 2010;1(3):239-243.

Abstract

Continuous and adequate BCR-ABL1 tyrosine kinase inhibitors (TKI) dosing is essential to achieve optimal therapeutic outcomes in patients with chronic myeloid leukemia (CML). Hence, patient adherence, defined as the extent to which a person’s behavior corresponds with the agreed recommendations of a healthcare provider, is critical. Though often trivialized as a patient problem, adherence behavior is influenced also by the clinician and the healthcare system, the disease and its treatment, and economic and social factors. In this paper, the issue of non compliance in patients with CML treated with TKI is reviewed. Possible interventions how to improve the adherence is also discussed.
Hematologia 2010; 1, 3: 239-243

Article available in PDF format

View PDF (Polish) Download PDF file



Hematology in Clinical Practice